 | ||
Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor. It also inhibits mTOR. It is being investigated as a possible cancer treatment.
It has been shown to be toxic to Waldenström's macroglobulinemia cells.
It was the first PI3K inhibitor to enter clinical trials, in 2006.
A phase IB/II clinical trial for locally advanced or metastatic HER2 negative breast cancer has completed.
A phase II clinical trial for advanced pancreatic neuroendocrine tumors (pNET) has reported results.
References
Dactolisib Wikipedia(Text) CC BY-SA